Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -32.29% is 18% below its 5-year average of -27.38%, near the low end of its 5-year range (-38.55%–-15.96%).
38.70% below its 12-month average of -23.28%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.65%.
RETURN ON ASSETS (ROA)
-32.29%
RETURN ON ASSETS (ROA) AVG TTM
-23.28%
RETURN ON ASSETS (ROA) AVG 3Y
-25.06%
RETURN ON ASSETS (ROA) AVG 5Y
-27.38%
RETURN ON ASSETS (ROA) AVG 10Y
-34.61%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-38.70%
CURRENT VS 3Y AVG
-28.84%
CURRENT VS 5Y AVG
-17.93%
CURRENT VS 10Y AVG
+6.71%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 784 covered companies
CURRENT VS SECTOR MEDIAN
-2.59%
vs the sector median at left
ProQR Therapeutics N.V.
Market Cap
$173.23M
Return on Assets (ROA)
-32.29%
TTM Avg
-23.28%
3Y Avg
-25.06%
5Y Avg
-27.38%
Market Cap
$172.81M
Return on Assets (ROA)
-41.88%
TTM Avg
-12.18%
3Y Avg
-27.40%
5Y Avg
-32.78%
Market Cap
$172.53M
Return on Assets (ROA)
-534.43%
TTM Avg
-94.69%
3Y Avg
-82.47%
5Y Avg
-71.30%
Market Cap
$175.39M
Return on Assets (ROA)
-38.62%
TTM Avg
-32.73%
3Y Avg
-28.05%
5Y Avg
-37.08%
Market Cap
$170.49M
Return on Assets (ROA)
-22.20%
TTM Avg
3.18%
3Y Avg
2.72%
5Y Avg
6.35%
Market Cap
$176.55M
Return on Assets (ROA)
-6.21%
TTM Avg
-15.18%
3Y Avg
-15.88%
5Y Avg
-16.43%
Market Cap
$176.97M
Return on Assets (ROA)
-79.26%
TTM Avg
-73.67%
3Y Avg
-58.36%
5Y Avg
-102.57%
Market Cap
$169.76M
Return on Assets (ROA)
-28.07%
TTM Avg
-34.40%
3Y Avg
-29.52%
5Y Avg
-36.05%
Market Cap
$169.56M
Return on Assets (ROA)
-34.75%
TTM Avg
-23.73%
3Y Avg
-25.63%
5Y Avg
-26.84%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProQR Therapeutics N.V. (PRQR) | $173.23M | -32.29% | -23.28% | -25.06% | -27.38% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.81M | -41.88% | -12.18% | -27.40% | -32.78% |
| Cue Biopharma, Inc. (CUE)vs › | $172.53M | -534.43% | -94.69% | -82.47% | -71.30% |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.39M | -38.62% | -32.73% | -28.05% | -37.08% |
| Organogenesis Holdings Inc. (ORGO)vs › | $170.49M | -22.20% | 3.18% | 2.72% | 6.35% |
| Journey Medical Corporation (DERM)vs › | $176.55M | -6.21% | -15.18% | -15.88% | -16.43% |
| Yarrow Bioscience Inc (YARW)vs › | $176.97M | -79.26% | -73.67% | -58.36% | -102.57% |
| MediWound Ltd. (MDWD)vs › | $169.76M | -28.07% | -34.40% | -29.52% | -36.05% |
| Nkarta, Inc. (NKTX)vs › | $169.56M | -34.75% | -23.73% | -25.63% | -26.84% |
| OptimizeRx Corp. (OPRX)vs › | $166.07M | 2.80% | -4.42% | -6.73% | -5.05% |
ROA
-32.3%
ROE
-54.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.60% |
| 2024-12-31 | -15.96% |
| 2023-12-31 | -18.46% |
| 2022-12-31 | -35.23% |
| 2021-12-31 | -25.49% |
| 2020-12-31 | -38.55% |
| 2019-12-31 | -43.01% |
| 2018-12-31 | -29.28% |
| 2017-12-31 | -68.43% |
| 2016-12-31 | -56.56% |
| 2015-12-31 | -19.16% |
| 2014-12-31 | -8.70% |
| 2013-12-31 | -52.41% |
| 2012-12-31 | 0.00% |
